Skip to main content

Month: May 2021

Small Pharma Provides Update to Patent Portfolio Including Receipt of an in Order for Grant Notice for its Patent Related to Psychedelic Tryptamines

LONDON, May 07, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), an IP-led neuropharmaceutical company, is pleased to announce an update on its patent portfolio since the filing of its filing statement on April 23, 2021. The Company announces that it has received an in order for grant notice in the United Kingdom for one of its patents related to psychedelic tryptamines. This UK patent will be the first one to receive an in order for grant notice from within the Company’s growing patent portfolio for psychedelic-based medicines. The Company has also filed two new patent applications and now has 31 patents pending. Updates to Patent PortfolioThe Company has received notice that its UK patent application GB2008303.6 is in order for grant. This UK patent application will cover a range of N,N-dimethyltryptamine...

Continue reading

Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit

Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will present at the Q2 Virtual Investor Summit on Tuesday, May 18th at 4:15 PM ET. In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website. A...

Continue reading

Man Group PLC : Form 8.3 – John Laing Group plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Man Group PLC(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree John Laing Group plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an opening position...

Continue reading

Brookfield Property Partners Reports First Quarter 2021 Results

All dollar references are in U.S. dollars, unless noted otherwise. BROOKFIELD NEWS, May 07, 2021 (GLOBE NEWSWIRE) — Brookfield Property Partners L.P. (NASDAQ: BPY; NASDAQ: BPYU; TSX: BPY.UN) (“BPY” or the “Partnership”) today announced financial results for the quarter ended March 31, 2021. “While we continue to experience challenges in certain of our operations and markets due to the ongoing consequences of the pandemic and global economic slowdown, we remain encouraged by a recovery in activity in select sectors within our business,” said Brian Kingston, CEO of Brookfield Property Partners. Financial Results Net income for the quarter ended March 31, 2021 was $731 million or $0.25 per LP unit compared to a loss of $373 million or $(0.49) per LP unit for the same period in 2020. This quarter benefited from gains in...

Continue reading

IBI Group Partners on Ford’s New Dearborn Campus Building to Advance the Future of Mobility

Global design and technology firm collaborates with automotive giant to transform its R&E facility into an innovation center SOUTHFIELD, Mich., May 07, 2021 (GLOBE NEWSWIRE) — Global design and technology firm, IBI Group (TSX: IBG), is lead architect on Ford Motor Company’s new Research & Engineering Center which is set to centralize Ford’s operations in Michigan and support increased innovation and collaboration. IBI Group is leading the project’s architecture, engineering, and landscape design in partnership with Snøhetta and Ghafari Associates. The firm’s expertise in technology-driven design, coupled with its smart cities portfolio, is contributing to the world-class transformation of Ford’s Dearborn Campus. The facility is expected to further establish Ford’s competitive edge in the future of mobility, and is set...

Continue reading

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

Results presented at the European Calcified Tissue Society Congress provide first evidence of increased plasma pyrophosphate (PPi) levels and reduced calcification with an enzyme replacement therapy in an animal model of PXE BOSTON, May 07, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today presented preclinical data suggesting the utility of its lead clinical development candidate, INZ-701, as a potential treatment for ABCC6 Deficiency. The data, presented at the virtual European Calcified Tissue Society Annual Congress (ECTS, May 6-8), are the first to show that an enzyme replacement therapy (ERT) increased plasma pyrophosphate (PPi) levels and reduced calcification in an animal model of ABCC6 Deficiency. ABCC6...

Continue reading

Notice of Knight Therapeutics’ First Quarter 2021 Results Conference Call

MONTREAL, May 07, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2021 financial results on Friday, May 14, 2021 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Friday, May 14, 2021 Time: 8:30 a.m. ET Telephone: Toll Free: 888-506-0062 or International 973-528-0011 Webcast: www.gud-knight.com or WebcastThis is a listen-only audio webcast. Media Player is required to listen to the broadcast. Replay: An archived replay will be available for 30 days at www.gud-knight.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty...

Continue reading

Iterum Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on May 14, 2021

DUBLIN, Ireland and CHICAGO, May 07, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2021 financial results before the open of the U.S. financial markets on Friday, May 14, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business. To register for the conference call please use this link: https://www.incommglobalevents.com/registration/client/7304/iterum-therapeutics-1st-quarter-2021-financial-results-conference-call/.    After registering, a confirmation...

Continue reading

Applied Materials Announces Q2 FY2021 Earnings Webcast

SANTA CLARA, Calif., May 07, 2021 (GLOBE NEWSWIRE) — Applied Materials, Inc. will hold a webcast to discuss its second quarter of fiscal 2021 financial results on Thursday, May 20, 2021 at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast will be accessible via the Applied Materials website at: https://ir.appliedmaterials.com. A replay will be available on the same day beginning at 8:00 p.m. ET / 5:00 p.m. PT. About Applied MaterialsApplied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. Our expertise in modifying materials at atomic levels and on an industrial scale enables customers to transform possibilities into reality. At Applied Materials, our innovations make possible the technology shaping the future. Learn more at www.appliedmaterials.com. Contact:Ricky...

Continue reading

TC Energy reports solid first quarter operating performance

Continues to advance $20 billion secured capital program following formal suspension of Keystone XL CALGARY, Alberta, May 07, 2021 (GLOBE NEWSWIRE) — TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) today announced a net loss attributable to common shares for first quarter 2021 of $1.1 billion or $1.11 per share compared to net income of $1.1 billion or $1.22 per share for the same period in 2020. Excluding an asset impairment charge related to the formal suspension of Keystone XL and certain other specific items, comparable earnings for first quarter 2021 were $1.1 billion or $1.16 per common share compared to $1.1 billion or $1.18 per common share in 2020. TC Energy’s Board of Directors also declared a quarterly dividend of $0.87 per common share for the quarter ending June 30, 2021, equivalent to $3.48...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.